Abstract:The use of existing mouse models in cancer research is of utmost importance as they aim to explore the casual link between candidate cancer genes and carcinogenesis as well as to provide models to develop and test new therapies. However, faster progress in translating mouse cancer model research into the clinic has been hampered due to the limitations of these models to better reflect the complexities of human tumors. Traditionally, immunocompetent and immunodeficient mice with syngeneic and xenografted tumors transplanted subcutaneously or orthotopically have been used. These models are still being widely employed for many different types of studies, in part due to their widespread availability and low cost. Other types of mouse models used in cancer research comprise transgenic mice in which oncogenes can be constitutively or conditionally expressed and tumor-suppressor genes silenced using conventional methods, such as retroviral infection, microinjection of DNA constructs, and the so-called "gene-targeted transgene" approach. These traditional transgenic models have been very important in studies of carcinogenesis and tumor pathogenesis, as well as in studies evaluating the development of resistance to therapy. Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)-based genome editing approach has revolutionized the field of mouse cancer models and has had a profound and rapid impact on the development of more effective systems to study human cancers. The CRISPR/Cas9-based transgenic models have the capacity to engineer a wide spectrum of mutations found in human cancers and provide solutions to problems that were previously unsolvable. Recently, humanized mouse xenograft models that accept patient-derived xenografts and CD34+ cells were developed to better mimic tumor heterogeneity, the tumor microenvironment, and cross-talk between the tumor and stromal/immune cells. These features make them extremely valuable models for the evaluation of investigational cancer therapies, specifically new immunotherapies. Taken together, improvements in both the CRISPR/Cas9 system producing more valid mouse models and in the humanized mouse xenograft models resembling complex interactions between the tumor and its environment might represent one of the successful pathways to precise individualized cancer therapy, leading to improved cancer patient survival and quality of life.

Transgenic mouse models of inhibition of tumor angiogenesis

Patient-derived Human Tumour Tissue Xenografts in Immunodeficient Mice: a Systematic Review

Experimental mouse models for translational human cancer research

Humanized Rodent Models for Cancer Research

Transgenic Mouse Models in Cancer Research

Knockout mouse models and mammary tumorigenesis.

Research Development of Tumor Angiogenesis and Angiogenesis Inhibitors

Advances in Prostate Cancer Research Models: from Transgenic Mice to Tumor Xenografting Models

Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases.

Development of humanized mouse with patient‐derived xenografts for cancer immunotherapy studies: A comprehensive review

Transgenic and gene knockout mice in gastric cancer research

Anti-angiogenic Active Immunotherapy: a New Approach to Cancer Treatment

[Advances in the Research of Mechanisms of Promotion of Vascularization by Angiogenin and Its Application].

Advances of Regulatory Factors on Tumor Angiogenesis

Cancer Gene Therapy Targeting Angiogenesis: an Updated Review.

Application of genetically engineered mice model in the research of gastrointestinal tumor

Advances in tumor vascular growth inhibition

Mouse models of breast cancer in preclinical research

Genetically engineered mouse models in oncology research and cancer medicine

Mouse Models of Thyroid Cancer: Bridging Pathogenesis and Novel Therapeutics.

Conditional Knockout Mouse Models of Cancer